Cepheid and BioMerieux to Develop, Market Sepsis Assays | GenomeWeb
NEW YORK (GenomeWeb News) — Cepheid and BioMerieux plan to develop and market a line of sepsis tests, the companies said today.
 
The companies said they will develop assays to identify fungi and bacteria and genetic markers for antibiotic resistance. Cepheid and BioMerieux also said that the panel could be used to identify hospital-acquired pneumonia.
 
The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.